GLYCOPYRROLATE | N022571 | MERZ PHARMACEUTICALS LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2021-07-15 | Terminated 2021-09-22 | — | |
| D. Del. | 2020-12-23 | Terminated 2021-06-03 | — | |
| D. Del. | 2020-06-24 | Terminated 2020-10-30 | — | |
| D. Del. | 2019-11-20 | Terminated 2020-02-14 | — | |
Merz Pharmaceuticals LLC v. Par Pharmaceutical Inc. et al 2 patentsANDA 204438glycopyrrolate | D. Del. | 2012-12-17 | Terminated 2013-11-13 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Merz North America (Buchanan, Ingersoll and Rooney PC) FDA-2014-P-0830 · 4 docket documents Merz North America, through counsel Buchanan Ingersoll and Rooney PC, filed this citizen petition pursuant to sections 505(b)(1) and 505A of the Federal Food, Drug, and Cosmetic Act requesting that the FDA Commissioner grant six-month pediatric exclusivity for Cuvposa (glycopyrrolate oral solution 1 | Other | 2014-07-01 | Denied | Merz North America (Buchanan, Ingersoll and Rooney PC) |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.01
per ml
Lowest NADAC/Unit
$1.01
per ml
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00259050116CUVPOSA 1 MG/5 ML SOLUTION | $1.01 | ML | Brand | $0.1752 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.